61704193f50f5f4c5f2ad472 amantadine-in-the-treatment-of-parkinson-s-disease-and-other-movement-disorders 2021-10-20T16:20:45.751Z 5e283dc93b5e750642253e57 793637c7-9615-42b1-905c-4827a6fab04c mas_evidence_types:Media%20and%20commentaries Media and commentaries Review discusses the pharmacological profile of amantadine and covers evidence from RCTs for the use of this drug for levodopa-induced dyskinesias in patients with Parkinson’s disease. It notes use for drug induced Parkinsonism and tardive dyskinesia lack a strong evidence base. <p>A related commentary notes the article provides insights into the reasons why amantadine is not widely used, highlighting that the complex pharmacology is still not fully understood, as well as the mechanisms behind its beneficial effects.</p> https://www.medicinesresources.nhs.uk/amantadine-in-the-treatment-of-parkinson-s-disease-and-other-movement-disorders.html <p><a href="https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00356-2/fulltext">Comment</a></p> https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00249-0/fulltext 2021-10-19T00:00:00Z 2021-10-20T16:19:31.319Z